Evid Based Nurs 12:12-13 doi:10.1136/ebn.12.1.12
  • Treatment

Intensive glucose control did not prevent important complications in type 2 diabetes

A Patel

Dr A Patel, University of Sydney, Sydney, New South Wales, Australia;


In type 2 diabetes, does intensive glucose control prevent adverse outcomes more than standard glucose control?



randomised controlled trial (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation [ADVANCE]).




blinded (outcome adjudication committee).

Follow-up period:

median 5 years.


215 centres in 20 countries worldwide.


11 140 patients ⩾55 years of age (mean age 66 y, 58% men) who had type 2 diabetes and a history of, or risk factors for, vascular disease. Patients requiring insulin were excluded.


intensive glucose control with gliclazide, modified-release, 30–120 mg/day, and other non-sulfonylurea drugs as needed to achieve a target glycated haemoglobin (HbA1c) concentration ⩽6.5% (n = 5571) or standard glucose control with drugs other than gliclazide (n = 5569).


composite of major macrovascular events (non-fatal myocardial infarction or stroke, or death from cardiovascular causes) and composite of major microvascular events (new or worsening nephropathy or retinopathy). Secondary outcomes included new-onset microalbuminuria and severe hypoglycaemia.

Patient follow-up:

95% (intention-to-treat analysis). …

Free Sample

This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of EBN.
View free sample issue >>

EBN Journal Chat

The EBN Journal Chat offers readers the opportunity to participate in discussion about research articles and commentaries from Evidence Based Nursing (EBN).

How to participate >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article